PYXIS ONCOLOGY INC (PYXS)

US7473241013 - Common Stock

4.2892  +0.14 (+3.35%)

Fundamental Rating

3

Taking everything into account, PYXS scores 3 out of 10 in our fundamental rating. PYXS was compared to 586 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PYXS as it has an excellent financial health rating, but there are worries on the profitability. PYXS does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PYXS has reported negative net income.
PYXS had a negative operating cash flow in the past year.
PYXS had negative earnings in each of the past 5 years.
PYXS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -26.25%, PYXS is doing good in the industry, outperforming 74.27% of the companies in the same industry.
PYXS's Return On Equity of -31.39% is fine compared to the rest of the industry. PYXS outperforms 78.22% of its industry peers.
Industry RankSector Rank
ROA -26.25%
ROE -31.39%
ROIC N/A
ROA(3y)-42.24%
ROA(5y)-53.3%
ROE(3y)-54.28%
ROE(5y)-76.2%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PYXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, PYXS has more shares outstanding
There is no outstanding debt for PYXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.16 indicates that PYXS is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.16, PYXS is in the better half of the industry, outperforming 69.64% of the companies in the same industry.
PYXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.16
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

PYXS has a Current Ratio of 12.19. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
PYXS's Current ratio of 12.19 is amongst the best of the industry. PYXS outperforms 82.68% of its industry peers.
PYXS has a Quick Ratio of 12.19. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 12.19, PYXS belongs to the best of the industry, outperforming 82.68% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.19
Quick Ratio 12.19

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.90% over the past year.
EPS 1Y (TTM)48.9%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q88.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A

3.2 Future

PYXS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.10% yearly.
Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 227.47% on average per year.
EPS Next Y49.94%
EPS Next 2Y15.69%
EPS Next 3Y9.51%
EPS Next 5Y2.1%
Revenue Next Year2599.95%
Revenue Next 2Y73.2%
Revenue Next 3Y277.97%
Revenue Next 5Y227.47%

3.3 Evolution

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PYXS. In the last year negative earnings were reported.
Also next year PYXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.69%
EPS Next 3Y9.51%

More info and screens

0

5. Dividend

5.1 Amount

PYXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (5/20/2024, 12:05:52 PM)

4.2892

+0.14 (+3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap252.55M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.25%
ROE -31.39%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 12.19
Quick Ratio 12.19
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)48.9%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y49.94%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y